HLA-A*11:01-presented Epstein-Barr virus latent membrane protein 2-derived peptide (HLA-A*11:01/EBV LMP2)

The HLA-A*11:01-presented Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2)-derived peptide is a specific peptide-major histocompatibility complex (pMHC) target used in immunotherapy (Source: Lion TCR, 2023). LMP2 is a viral protein expressed during EBV latency and is frequently found in EBV-associated malignancies such as nasopharyngeal carcinoma (NPC) and certain lymphomas (Source: PubMed, PMID: 10823877). The HLA-A*11:01 allele is particularly prevalent in Southeast Asian and Chinese populations, where NPC incidence is high, making this specific pMHC a critical target for precision medicine (Source: Allele Frequency Net Database). Therapeutic strategies targeting this complex include T-cell receptor (TCR)-engineered T-cells, such as LioCyx-M, and vaccines designed to elicit a cytotoxic T-lymphocyte (CTL) response against cells presenting these viral fragments (Source: ClinicalTrials.gov, NCT04709159). By specifically recognizing the LMP2 peptide in the context of HLA-A*11:01, these therapies aim to selectively eliminate EBV-positive tumor cells while sparing healthy tissue. However, challenges include potential immune evasion through HLA downregulation and the need for high TCR specificity to avoid cross-reactivity with similar human peptides (Source: Frontiers in Immunology, 2021).

Other names

HLA-A*11:01/LMP2 complexEBV LMP2 peptide-HLA-A*11:01LMP2-derived peptide presented by HLA-A*11:01SSC peptide-HLA-A*11:01 complex

Recognition by specific T-cell receptors (TCRs) leading to T-cell activation and lysis of EBV-infected or malignant cells.